<DOC>
	<DOCNO>NCT02596971</DOCNO>
	<brief_summary>This Phase Ib/II , open-label , multicenter , non-randomized study evaluate safety , efficacy , pharmacokinetics induction treatment consist atezolizumab combination either obinutuzumab + bendamustine ( Atezo-G-benda ) obinutuzumab + CHOP ( Atezo-G-CHOP ) participant FL atezolizumab + rituximab + chemotherapy ( Atezo-R-CHOP ) participant DLBCL , follow post-induction treatment consist either atezolizumab plus obinutuzumab ( Atezo-G ) participant FL achieve complete response ( CR ) partial response ( PR ) end induction ( EOI ) atezolizumab alone participant DLBCL achieve CR EOI .</brief_summary>
	<brief_title>A Study Atezolizumab Combination With Either Obinutuzumab Plus Bendamustine Obinutuzumab Plus ( + ) Cyclophosphamide , Doxorubicin , Vincristine , Prednisone ( CHOP ) Participants With Follicular Lymphoma ( FL ) Rituximab + CHOP Participants With Diffuse Large B-Cell Lymphoma ( DLBCL )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Obinutuzumab</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 , 1 , 2 For participant enrol safety runin phase : lymphoma classify either relapse refractory FL treatment least one prior chemoimmunotherapy regimen previously untreated Grade 1 , 2 , 3a FL require treatment For participant enrolled expansion phase : lymphoma classify either previously untreated Grade 1 , 2 , 3a FL require treatment previously untreated advanced DLBCL Histologically document cluster differentiation 20 ( CD20 ) positive lymphoma Fluorodeoxyglucoseavid lymphoma At least one bidimensionally measurable lesion ( great [ &gt; ] 1.5 centimeter large dimension CT scan magnetic resonance imaging ) Availability representative tumor specimen correspond pathology report retrospective central confirmation diagnosis FL DLBCL For woman postmenopausal surgically sterile : agreement remain abstinent ( refrain heterosexual intercourse ) use contraceptive method result failure rate less [ &lt; ] 1 percent [ % ] per year treatment period least 18 month last dose study treatment participant AtezoGbenda AtezoGCHOP treatment group least 12 month last dose study treatment participant AtezoRCHOP treatment group For men : agreement remain abstinent use contraceptive measure agreement refrain donate sperm Histological evidence transformation FL highgrade Bcell nonHodgkin 's lymphoma ( NHL ) Central nervous system lymphoma leptomeningeal infiltration For participant DLBCL : preplanned consolidative radiotherapy Treatment systemic immunosuppressive medication , include , limited , prednisone , azathioprine , methotrexate , thalidomide , antitumor necrosis factor agent within 2 week prior Day 1 Cycle 1 For participant relapsed refractory FL : prior allogeneic autologous stem cell transplantation , anthracycline therapy , treatment fludarabine alemtuzumab within 12 month prior Day 1 Cycle 1 , treatment monoclonal antibody , radioimmunoconjugate , antibodydrug conjugate within 4 week prior Day 1 Cycle 1 , radiotherapy , chemotherapy , hormonal therapy , target smallmolecule therapy within 2 week prior Day 1 Cycle 1 History solid organ transplantation History severe allergic anaphylactic reaction know sensitivity humanize murine monoclonal antibody Known hypersensitivity biopharmaceuticals produce Chinese hamster ovary cell component atezolizumab , obinutuzumab , rituximab , bendamustine formulation , include mannitol Positive hepatitis B surface antigen ( HBsAg ) , total hepatitis B core antibody ( HBcAb ) , hepatitis C virus ( HCV ) antibody screen History progressive multifocal leukoencephalopathy Vaccination live virus vaccine within 28 day prior Day 1 Cycle 1 History malignancy , autoimmune disease , significant , uncontrolled concomitant disease could affect compliance protocol interpretation result Major surgical procedure diagnosis within 28 day prior Day 1 Cycle 1 , anticipation major surgical procedure course study For participant receive CHOP : leave ventricular ejection fraction ( LVEF ) &lt; 50 % multiplegated acquisition ( MUGA ) scan echocardiogram Inadequate hematologic , renal , liver function ( unless due underlie lymphoma )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>